Neuroendocrine Tumors
Conditions
Brief summary
The objective of this study is to describe the use of resources and the costs associated with controlled or uncontrolled CS in patients with NETs in Spain.
Interventions
OTHERData collection
The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
Sponsors
Ipsen
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient 18 years of age or older. * Patient with a diagnosis of NET (G1 or G2) treated with Somatostatin Analogues (SSAs) to manage their symptoms. 1. Group A: patient who has had at least one episode of uncontrolled CS, according to medical criteria, since the start of treatment. 2. Group B: patient who has not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months. * Patient able to read and understand the study questionnaires. * Patient who has given written informed consent to participate in the study.
Exclusion criteria
* Patient participating in another clinical study when invited to participate in this study. * Patient with another severe malignant disease. * Patient who cannot meet the requirements established in the protocol (non-compliant or unfit to fill in the questionnaires). * Patient with symptoms or diseases that could be confused with CS or render CS more difficult to evaluate: right cardiomyopathy or diarrhoea of any aetiology other than NET.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Use of resources and costs in patients with controlled or uncontrolled CS | Day 1 (Group A retrospective data collection - 3 months before and up to 6/12 months after the last uncontrolled carcinoid episode. Group B retrospective data collection - up to 6/12 months before the date of enrolment) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical characteristics and therapeutic management of patients with NET and controlled or uncontrolled CS | Day 1 (Group A retrospective data collection - 3 months before and up to 6/12 months after the last uncontrolled carcinoid episode. Group B retrospective data collection - up to 6/12 months before the date of enrolment) | A descriptive analysis of the diagnostic process; time of evolution of the disease; treatment prescribed following the diagnosis of NET and reason for choice; time elapsed from the diagnosis of NET to the first therapeutic intervention; prior and current drug treatment for NET and CS (active substance, type of treatment \[rapid action vs prolonged action\], dose and duration); concomitant diseases (including cardiac complications); New York Heart Association (NYHA) functional classification (I-IV); proBNP, chromogranin A and 5HIAA value; and value of the last echocardiogram, as well as any other treatments and interventions that the patient may have undergone (Yes/No, active substance and type of intervention) will be performed. The results will be compared between the two groups of patients using the paired t test for continuous variables and the Cochran-Mantel-Haenszel test or conditional logistic regression for categorical variables. |
| Relationship between the state of health perceived by the patient and the clinical status of the disease reported by the physician. | Day 1 (Group A retrospective data collection - 3 months before and up to 6/12 months after the last uncontrolled carcinoid episode. Group B retrospective data collection - up to 6/12 months before the date of enrolment) | — |
Countries
Spain
Outcome results
None listed